Single B cell sorting is a new technology that isolates single antigen-specific plasma cells to retrieve Native™ antibodies with extremely high in vivo specificity and affinity. Creative Biolabs is happy to offer a comprehensive range of Native™ antibody discovery services based on our advanced B cell sorting platform.
The hybridoma technique introduced in 1975 made it possible to harvest pure monoclonal antibodies (mAbs) on large scale, which laid the foundation for antibody development and clinical applications. Later in 1986, the Food and Drug Administration approved the first mAb, a murine anti-CD3 mAb, for preventing kidney transplant rejection. More than 80 therapeutic mAbs have been licensed for the treatment of various diseases ever since, among which about 30 therapeutic mAbs on the market are intended for tumor or cancer treatment, some for autoimmune diseases, and others for infectious diseases, such as human immunodeficiency virus infection and coronavirus-2019 infection. Moreover, hundreds of therapeutic mAbs have been developed and evaluated in clinical trials. Approximately 90% of these therapeutic mAbs were designed for cancer and tumor treatment, and a minor proportion was developed for the treatment of neurological, allergic diseases, and other human diseases, such as multiple sclerosis, Alzheimer's disease, allergic asthma, etc. Therapeutic antibodies play an increasingly important role in precision medicine due to their targeting mechanisms.
Over these decades, a variety of in vitro technologies have been developed for antibody production and engineering, including transgenic animal technology, phage display technology, and single B cell antibody technology. Therapeutic antibody development undergoes four stages, murine antibody, chimeric antibody, humanized antibody, and fully human antibody, by which immunogenicity of therapeutic antibody is rapidly reduced to better applied for the treatment of human diseases.
Fig.1 Timeline from 1975 showing the successful development of therapeutic antibodies.1, 3
One of the troubling challenges is the development and discovery of therapeutic antibodies against uncommon targets and antibodies for rare disease therapy. In addition to common antibody targets or the existing disease antigens, there are many uncommon targets and unidentified biomarkers related to diseases, such as rare targets with a low mutation rate in lung cancer. Antibody development against these uncommon targets is challenging because of the low mutation frequency and the difficulty in obtaining targets. Rare diseases are a category of disorders that affect only a small number of people, most of which are inherited and present throughout a person's life. Several therapeutic antibodies have been approved for the treatment of rare diseases, such as an anti-C5 antibody for the treatment of atypical hemolytic uraemic syndrome and myasthenia gravis, an anti-IL-1β antibody for the treatment of cryopyrin-associated periodic syndromes, a bispecific antibody for the treatment of hemophilia.
Currently, antibody development in rare disease therapy is relatively uncommon but holds great potential. In contrast to other antibody technologies, single B cell antibody technology has great advantages in the antibody development against uncommon targets and therapeutic antibody discovery for rare disease therapy, since antibodies developed by single B cell technology are characterized by:
Fig.2 Workflows and timelines of antibody development by single B cell technology.2, 3
As a pioneer and the undisputed global leader in antibody discovery and manufacturing, Creative Biolabs has developed a unique platform to develop Native™ monoclonal antibodies by single B cell technology. Our highly professional scientists are confident in providing a wide range of antibody development services for various targets and diseases. Our featured services mainly including but not limited to:
If you are interested or have any questions, please don’t hesitate to contact us.
References
